The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
How an aquarium pet became a scientific star in childhood cancer research
Seth Corey, M.D., M.P.H., joined VCU Massey Cancer Center and Children’s Hospital of Richmond at VCU (CHoR) in October 2015 as the chief of the Division of Hematology, Oncology, and Stem Cell Transplantation in the Department of Pediatrics. He is also the inaugural Children’s Hospital Foundation Endowed Chair in Pediatric Cancer Research, which is funded by a large grant from Children’s Hospital Foundation and a gift from Connor’s Heroes. Additionally, he is the co-leader of Massey’s Cancer Molecular Genetics research program and a professor of pediatrics and microbiology/immunology at the VCU School of Medicine. A board-certified pediatric oncologist and cancer researcher, Corey specializes in leukemias, bone marrow failure, and stem cell transplantation.
VCU’s cancer research on display at Massey’s annual Research Retreat
VCU Massey Cancer Center’s annual Cancer Research Retreat received an exceptional response despite following on the heels of one of the strongest storms Richmond has experienced in years. The gloomy weather did not hamper the bright scientific discussion emanating from the morning’s lectures and the afternoon’s poster session.
Massey physician-researcher helps develop and lead national breast cancer studies
VCU Massey Cancer Center physician-researcher Charles Geyer, M.D., co-developed and co-led two important national breast cancer clinical trials that were recently presented at the American Society of Clinical Oncology’s annual meeting in Chicago. One study was presented in the “Best of ASCO” Program, which presents the scientific and educational highlights of the meeting.
Ten years later… Still one in a million
In March of 2003, I was having pain in my right upper chest that initially occurred only when I laughed. Eventually the pain continued to worsen, so I made an appointment with my primary care physician. After many tests and procedures, fluid-filled sacks were found on my liver. The following week, I was scheduled for a liver biopsy.
I woke up from that biopsy and my life had been changed forever.
Novel combination therapy developed at Massey shows strong response in patients with advanced solid tumors
A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. Approximately 61 percent of these patients experienced some degree of tumor growth delay, with multiple partial responses and one complete response. A phase 2 study testing the same combination of the drugs sorafenib and pemetrexed in patients with recurrent or metastatic triple negative breast cancer is now open at Massey.